Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emisphere Technologies, a biopharmaceutical company, has announced that Novartis Pharma and Nordic Bioscience have initiated a second multi-center Phase III study exploring the safety and efficacy of an oral formulation of salmon calcitonin using Emisphere's proprietary Eligen technology to treat patients with osteoarthritis of the knee.
Subscribe to our email newsletter
This second study, designed to meet the FDA requirements for US registration, will examine patients between 51 and 80 years old suffering from painful symptoms of knee osteoarthritis. The study will be conducted in multiple sites, including the US, with an estimated completion during the second half of 2011.
Michael Novinski, president and CEO of Emisphere, said: “This second phase III study is a significant step in facilitating the commercialization of oral salmon calcitonin in combination with our Eligen drug delivery technology in the US and worldwide. This combination may provide a solution to the growing problem of osteoarthritis.”